Hans Hammers, MD, PhD

Articles

Future Outlooks in the Treatment of Advanced RCC

December 27th 2023

Experts close the discussion by sharing insights on the future in advanced RCC, emphasizing the development of emerging agents and combination regimens for the treatment landscape.

Data Updates in Advanced RCC from 2023 IKCS: North America

December 27th 2023

Drs Rini and Hammers discuss additional clinical readouts from the 2023 IKCS: North America meeting including emerging agents for advanced RCC such as belzutifan and zanzalitinib.

Impact of Treatment Selection and Real-World Outcomes in Advanced RCC

December 20th 2023

Brian Rini, MD, discusses the impact of real-world outcomes on treatment selection, highlighting frontline combination axitinib plus pembrolizumab in advanced RCC.

Tackling Toxicity Management in Combination Regimens for Advanced RCC

December 20th 2023

A comprehensive discussion on toxicity management and patient tolerability for combination regimens in the setting of advanced RCC.

CLEAR Trial: Lenvatinib plus Pembrolizumab in Advanced RCC

December 13th 2023

Experts highlight key clinical updates from the CLEAR trial presented at the 2023 IKCS: North America congress, assessing lenvatinib plus pembrolizumab in patients with advanced RCC.

The Evolution of Advanced Renal Cell Carcinoma

December 13th 2023

Brian Rini, MD, and Hans Hammers, MD, PhD, discuss the evolution of management for advanced renal cell carcinoma (RCC), noting the role of biomarkers and its use in practice.

Dr Hammers on a Case Presentation in Advanced RCC

October 21st 2023

Hans Hammers, MD, PhD, discusses a case presentation of a patient with advanced renal cell carcinoma.

Dr Hammers on Unmet Needs in the Frontline Treatment of RCC

September 18th 2023

Hans Hammers, MD, PhD, discusses areas of controversy and remaining unmet needs in the treatment of patients with renal cell carcinoma.

Dr Hammers on Ongoing Investigations in Advanced RCC

August 23rd 2023

Hans Hammers, MD, PhD, discusses ongoing and planned investigations with the use of HIF2α inhibitors and triplet therapies in patients with advanced renal cell carcinoma.

Genetic Counseling for Patients with Non-Clear Cell RCC

April 26th 2023

The panel closes their discussion with a look at the standards for genetic counseling for patients with non-clear cell RCC.

Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC

April 26th 2023

The panel discusses the best approaches to treating patients with non-clear cell RCC.

Preferred Treatment Regimens for Refractory RCC

April 19th 2023

The panel shares their preferred treatment regimens for patients with refractory renal cell carcinoma.

Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC

April 19th 2023

Hans Hammers, MD, presents a profile of a 47-year-old male with refractory renal cell carcinoma.

Updates in the Adjuvant Treatment of Metastatic RCC

April 12th 2023

The panel discusses recent clinical trial data in the adjuvant treatment of metastatic renal cell carcinoma.

Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial

April 5th 2023

Drs Moshe Ornstein and Hans Hammers review data from the COSMIC-313 trial investigating ipilimumab, nivolumab, and cabozantinib for the frontline treatment of metastatic renal cell carcinoma.

Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment

April 5th 2023

The panel provides an overview of novel double combination therapies currently under investigation.

Treatment Approaches for Patients with RCC and Bone Metastases

March 31st 2023

Mehmet Asim Bilen, MD, details how he approaches IO/TKI therapy for patients with renal cell carcinoma with bone metastases.

Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC

March 31st 2023

The panel discusses the use of quality-of-life clinical trial data in metastatic renal cell carcinoma and how liver and brain metastases affect treatment decision-making.

Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

March 23rd 2023

Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.

Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

March 23rd 2023

Drs Moshe Ornstein and Mehmet Asim Bilen review updated data from the CheckMate 9ER and CLEAR trials investigating combination treatments for metastatic renal cell carcinoma.